Global Patent Index - EP 1237557 A1

EP 1237557 A1 2002-09-11 - GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE

Title (en)

GALENICAL PREPARATIONS OF DAPSONE AND RELATED SULPHONES, AND METHOD OF THERAPEUTIC AND PREVENTATIVE TREATMENT OF DISEASE

Title (de)

GALENISCHE PRÄPARATIONEN VON DAPSON UND VERWANDTEN SULPHONEN SOWIE METHODE ZUR THERAPEUTISCHEN UND PRÄVENTIVEN BEHANDLUNG VON ERKRANKUNGEN

Title (fr)

PREPARATIONS GALENIQUES DE DAPSONE ET DE SULFONES APPARENTES ET PROCEDE DE TRAITEMENT THERAPEUTIQUE ET PROPHYLACTIQUE DE LA MALADIES

Publication

EP 1237557 A1 (EN)

Application

EP 00983981 A

Priority

  • US 0033138 W
  • US 16972799 P

Abstract (en)

[origin: WO0141772A1] Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.

IPC 1-7 (main, further and additional classification)

A61K 31/70

IPC 8 full level (invention and additional information)

A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/136 (2006.01); A61K 31/145 (2006.01); A61K 31/16 (2006.01); A61K 31/167 (2006.01); A61K 31/185 (2006.01); A61K 31/426 (2006.01)

CPC (invention and additional information)

A61K 9/2059 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/205 (2013.01); A61K 9/2866 (2013.01); A61K 31/136 (2013.01); A61K 31/145 (2013.01); A61K 31/16 (2013.01); A61K 31/167 (2013.01); A61K 31/185 (2013.01); A61K 31/426 (2013.01); Y02A 50/411 (2018.01)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

EPO simple patent family

WO 0141772 A1 20010614; AU 2066401 A 20010618; EP 1237557 A1 20020911

INPADOC legal status


2005-01-19 [18D] APPLICATION DEEMED TO BE WITHDRAWN

- Effective date: 20040701

2002-09-11 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20020705

2002-09-11 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

2002-09-11 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO:

- Free text: AL;LT;LV;MK;RO;SI